SKLB-23bb 是一种口服生物可利用的 HDAC6 选择性抑制剂，还具有微管破坏能力，IC50为 17 nM。它比HDAC1和HDAC8选择性分别高 25 倍和 200 倍，IC50为 422 和 3398 nM。

SKLB-23bb is an orally bioavailable HDAC6-selective inhibitor and also has microtubule-disrupting ability.

In vivo efficacy evaluations of colorectal HCT116, acute myelocytic leukemia MV4-11, and B cell lymphoma Romas xenografts, SKLB-23bb more effectively inhibited the tumor growth than SAHA even at a 4-fold reduced dose or ACY-1215 at the same dose. SKLB-23bb is a potent oral anticancer candidate for selective HDAC6 inhibitor.

1815580-06-3

C21H24N4O4

396.447

DMSO:32 mg/mL (80.72 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years